Sanofi expands in rare disease

Posted 29 June 2022 AM

Sanofi is looking to expand its rare disease portfolio by bringing the first specific treatment for an inherited metabolic disorder called Acid sphingomyelinase deficiency (ASMD) to Australia.

Last week, the TGA granted the company an orphan drug designation for Xenpozyme, indicating the therapy could become available by mid-2023.

To see the whole article, please login